ViroPharma Announces Agreement With SIGA Technologies For Sale Of Biodefense Assets

ViroPharma Incorporated (Nasdaq:VPHM) announced that it has sold certain of its early stage biodefense assets, including compounds, assays and other intellectual property related to the development of antiviral drugs targeting the smallpox virus and viral hemorrhagic fever viruses, to SIGA Technologies, Inc. (Nasdaq:SIGA), a company that focuses on the development of products for the prevention and treatment of infectious diseases, with an emphasis on products for biological warfare defense. As consideration for such assets, SIGA Technologies paid ViroPharma $1,000,000 in cash and issued ViroPharma 1,000,000 shares of SIGA common stock.